Trinity Biotech (NASDAQ:TRIB) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a note issued to investors on Wednesday. The firm set a “buy” rating on the stock.

Trinity Biotech Price Performance

Shares of TRIB stock opened at $2.59 on Wednesday. Trinity Biotech has a 1-year low of $1.49 and a 1-year high of $5.50. The business’s fifty day moving average price is $1.89 and its 200 day moving average price is $2.16. The firm has a market capitalization of $19.74 million, a PE ratio of -0.93 and a beta of 1.17.

Trinity Biotech (NASDAQ:TRIB) last released its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. Equities research analysts expect that Trinity Biotech will post -2.17 earnings per share for the current fiscal year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.